机构:[1]Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China北京朝阳医院[2]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[3]Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China内科科室血液内科昆明医科大学附属第一医院[4]Department of Hematology, Chifeng Municipal Hospital, Chifeng, China[5]Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao, China[6]Department of Hematology, Affiliated Hospital of Hebei University, Baoding, China河北大学附属医院[7]Department of Hematology, The Fifth Medical Center of People's Liberation Army (PLA) General Hospital, Beijing, China[8]Department of Hematology, Heping Hospital Affiliated To Changzhi Medical College,Changzhi, China[9]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[10]Department of Hematology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Secience and Technology, Baotou, China内蒙古科技大学包头医学院[11]Department of Hematology, The Third People's Hospital Of Datong, Datong, China[12]Department of Hematology, Linfen People's Hospital, Linfen, China[13]Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China[14]Department of Hematology, Second hospital of Shanxi Medical University, Taiyuan, China[15]Department of Hematology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China[16]Department of Hematology, The Forth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[17]Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China[18]Department of Hematology, Beijing Jishuitan Hospital, Beijing, China[19]Department of Hematology, Peking University First Hospital, Beijing, China[20]Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China[21]Institution of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[22]The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou, China[23]Department of Hematology, Bayannur Hospital, Bayannur, China[24]Department of Hematology, Ordos Central Hospital, Ordos, China[25]Department of Hematology, Shanxi Cancer Hospital, Taiyuan, China[26]Department of Oncology, The First Hospital of Jilin University, Changchun, China[27]Department of Oncology, The First Hospital of Jilin University, Changchun, China[28]Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[29]Department of Hematology, Peking University Third Hospital, Beijing, China[30]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Beijing Natural Science Foundation
(7212041), Clinical Research Incubation Project (Beijing Chao-Yang Hospital,
Capital Medical University, CYFH202208), National Natural Science Foundation of
China (81974011), and National High Level Hospital Clinical Research Funding
(2022-PUMCH-B-048).
第一作者机构:[1]Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China[2]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shuaifuyuan No.1, Dongcheng District, Beijing 100005, China.[*2]Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University Gongtinanlu No. 8, Chaoyang District, Beijing 100020, China.
推荐引用方式(GB/T 7714):
Jian Yuan,Chang Long,Shi Ming-Xia,et al.Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment[J].BLOOD ADVANCES.2023,7(24):7581-7584.doi:10.1182/bloodadvances.2023011428.
APA:
Jian Yuan,Chang Long,Shi Ming-Xia,Sun Ying,Chu Xiao-Xia...&Gao Wen.(2023).Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.BLOOD ADVANCES,7,(24)
MLA:
Jian Yuan,et al."Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment".BLOOD ADVANCES 7..24(2023):7581-7584